You Position: Home > Paper
胰高血糖素样肽-1及相关制剂的降糖机制与应用进展
( views:240, downloads:56 )
- Author:
- No author available
- Journal Title:
- Journal of Naval General Hospital
- Issue:
- 4
- DOI:
- 10.3969/j.issn.1009-3427.2011.04.010
- Key Word:
- 糖尿病;胰高血糖素样肽-1;胰高血糖素样肽-1类似物;二肽基肽酶-Ⅳ抑制剂
Abstract： 胰高血糖素样肽-1是肠道L细胞分泌的一种十分重要的肠促胰岛素,具有促进胰岛素的分泌、抑制胰高血糖素释放、延缓胃排空、改善β细胞功能并阻止其凋亡等多重作用而发挥独特的降糖作用.胰高血糖素样肽-1的两大类药物,即二肽基肽酶-Ⅳ抑制剂和胰高血糖素样肽-1类似物作为新型的降糖药物在糖尿病治疗中发挥越来越重要的作用,是近年来糖尿病治疗药物研究的热点之一.
- [1]蒋筠,彭永德.人GLP-1类似物治疗2型糖尿病的研究进展[J].2010,(2).
- [2]Byung-Kwon Lee,Angela Wittelsberger,Beena E.Thomas,etc.The Mid-Region of Parathyroid Hormone(1-34)Serves as a Functional Docking Domain in Receptor Activation[J].2006,45(7).
- [3]Carolyn F, Deacon.Potential of liraglutide in the treatment of patients with type 2 diabetes.[J].2009,5(1).
- [4]Miura Y,Matsui H.Triphenyltin impairs a protein kinase A (PKA)-dependent increase of cytosolic Na+ and Ca2+ and PKA-independent increase of cytosolic Ca2+ associated with insulin secretion in hamster pancreatic beta-cells.[J].2006,216(3).
- [5]Irwin N,Harriott P,McClean PL,etc.Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice.[J].2007,42(4).
- [6]Seck T,Nauck M,Sheng D,etc.Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.[J].2010,64(5).
- [7]Rungby J,Schmitz O,Sturis J,etc.One Week's Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and alpha- and beta-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes.[J].2004,53(5).
- [8]Egan JM,Kim W.The role of incretins in glucose homeostasis and diabetes treatment.[J].2008,60(4).
- [9]Rosenstock J,Aguilar Salinas C,Klein.Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes.[J].2009,25(10).
- [10]Scherbaum WA,Nilsson PM,Lalanne G,etc.Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia*.[J].2008,10(8).
- [11]Dong M,Pinon DI,Zang M,etc.Spatial approximation between two residues in the mid-region of secretin and the amino terminus of its receptor. Incorporation of seven sets of such constraints into a three-dimensional model of the agonist-bound secretin receptor.[J].2003,278(48).
- [12]Baron AD,Fineman MS,Bicsak TA,etc.Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.[J].2003,26(8).
- [13]Grauschopf U.,Panzner S.,Reusch D.,etc.In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor[J].2002,96(2).
- [14]Suzuki, Yuko,Hui Zhang,Saito, Naoaki,etc.Glucagon-like Peptide 1 Activates Protein Kinase C through Ca<sup>2+</sup>-dependent Activation of Phospholipase C in Insulin-secreting Cells.[J].2006,281(39).
- [15]Schirra J,Goke B.The physiological role of GLP-1 in human: incretin, ileal brake or more?[J].2005,128(2).
- [16]Trautmann M,Kothare PA,Taylor K,etc.Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.[J].2007,30(6).
- [17]Arulmozhi DK,Portha B.GLP-1 based therapy for type 2 diabetes.[J].2006,28(1).
- [18]Drucker DJ,Nauck MA.The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.[J].2006,368(9548).
- [19]Meier JJ,Schmidt WE,Holst JJ,etc.Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes.[J].2003,88(6).